Results 191 to 200 of about 5,732 (211)

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. [PDF]

Proc Natl Acad Sci U S A
Leithner A, Staufer O, Mitra T, Liberta F, Valvo S, Kutuzov M, Dada H, Spaeth J, Zhou W, Schiele F, Reindl S, Nar H, Hoerer S, Crames M, Comeau S, Young D, Low S, Jenkins E, Davis SJ, Klenerman D, Nixon A, Pefaur N, Wyatt D, Dushek O, Kasturirangan S, Dustin ML.   +25 more
europepmc   +1 more source

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. [PDF]

J Mol Med (Berl)
Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, Abken H, Wölfel C, Theobald M, Hartwig UF.   +9 more
europepmc   +1 more source

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. [PDF]

J Immunother Cancer
Gaspar M, Natoli M, Castan L, Rahmy S, Korade M, Kelton C, Mulgrew K, Huhn O, Rees DG, Sigurdardottir A, Lloyd C, Taylor JJ, Brailey PM, Dallaway L, Toloczko A, Giraldo N, Broggi MAS, Kunihiro A, Abhishek S, He Y, Rong Y, Eyles J, Ball K, Fitzgerald J, Hammond SA, Cemerski S, Dovedi SJ, Cobbold M.   +27 more
europepmc   +1 more source

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy. [PDF]

J Clin Invest
Duffy AM, Goenka A, Azeem MI, Taz A, Potdar SV, Scott SA, Marin E, Kaufman JL, Hofmeister CC, Joseph NS, Gupta VA, Lonial S, Nooka AK, Dhodapkar MV, Dhodapkar KM.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future Oncology, 2022
Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki   +2 more
exaly  

Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy

Biomaterials, 2021
Jaeho Song, Nayoung Kim, Keehoon Jung
exaly  

Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method

European Journal of Pharmaceutical Sciences, 2021
Junsheng Xue, Dongyang Liu
exaly  

A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma

Molecular Immunology, 2023
Baizhi Li, Baihui Shan, Fuqiu Li
exaly  

Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys

Toxicological Sciences, 2022
Tod A Harper, Hervé Lebrec, Olivier Nolan-Stevaux   +2 more
exaly  

In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE)

Biomaterials, 2021
Han Lin, Kuo-Hsiang Chuang, Ming-Thau Sheu   +2 more
exaly